EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity.
Berg JL, Perfler B, Hatzl S, Uhl B, Reinisch A, Pregartner G, Berghold A, Penz T, Schuster M, Geissler K, Prokesch A, Müller-Tidow C, Hoefler G, Kashofer K, Wölfler A, Sill H, Caraffini V, Zebisch A.
Berg JL, et al. Among authors: pregartner g.
Leukemia. 2021 May;35(5):1521-1526. doi: 10.1038/s41375-021-01161-0. Epub 2021 Feb 15.
Leukemia. 2021.
PMID: 33589750
Free PMC article.
No abstract available.